The news: Strive Pharmacy plans to reintroduce a compounded semaglutide weight loss pill, per Endpoints News, despite regulatory and legal scrutiny.

Catch up quick: Hims & Hers announced it would sell a compounded version of Novo Nordisk’s new Wegovy pill for weight loss in February. However, it quickly scrapped those plans after Novo filed a patent infringement lawsuit and the FDA opened a broad investigation into the marketing of unapproved GLP-1 compounds.

Why it matters: As GLP-1 demand grows, telehealth companies in the weight loss drug space must choose between tie-ups with riskier compounding pharmacies or more stable deals with GLP-1 drugmakers Novo and Eli Lilly.

• Novo and Lilly are offering discounted GLP-1s to telehealth distribution partners—including GoodRx, Ro, WeightWatchers, and LifeMD—if they agree to stop selling compounded GLP-1s on their platforms.
• Telehealth partners are showing they can capture brand-name GLP-1 sales. GoodRx, for example, said in its Q4 call that it accounted for 20% of Wegovy pill self-pay sales during a single week in January.
• Ro and Weight Watchers are among those promoting branded GLP-1 brands in TV and digital ads—emphasizing effectiveness and trust in FDA-approved drugs.

Implications for telehealth marketers: The rapid rise and fall of Hims’ compounded pill plan underscores how quickly copycat GLP-1 strategies can be disrupted when patent holders and regulators intervene. Now the risk of relying on compounded GLP-1s may no longer outweigh the reward.

While Strive’s plans suggest some players are still willing to test regulatory gray areas, Hims’ broader retreat from compounded drugs as key to its business indicates even leading telehealth companies are reassessing the volatility. The more durable strategy for telehealth will likely center on pharma alliances and competing on customer experience, adherence, and value-added services such as personalized fitness coaching and meal planning.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.